We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently published a list of 10 Magnificent Dividend Growth Stocks to Invest In. In this article, we are going to take a ...

Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...

We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...

AbbVie Inc. closed 0.64% short of its 52-week high of $215.66, which the company reached on March 4th.

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity ...

AbbVie ABBV has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 13.09%. Currently, AbbVie has a market capitalization of $360.27 ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...